Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RECCE 327

Next Previous
Drug Profile

RECCE 327

Alternative Names: R 327; R-327G; RECCE-327

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Recce Pharmaceuticals
  • Developer Path BioAnalytics; Recce Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Antivirals; Foot disorder therapies; Polymers; Skin disorder therapies; Urinary anti-infective agents
  • Mechanism of Action Bacterial protein inhibitors; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer
  • Phase II Bacterial infections
  • Phase I/II Burn infections; Urinary tract infections
  • Preclinical COVID 2019 infections; Nosocomial pneumonia; Ventilator associated pneumonia
  • No development reported Clostridium infections; Influenza virus infections; Sepsis; Streptococcal infections

Most Recent Events

  • 19 Aug 2026 Recce Pharmaceuticals received HREC approval for amendment of phase III trial for Diabetic foot ulcer in Australia
  • 23 Jul 2026 Phase-III clinical trials in Diabetic foot ulcer in Australia, Indonesia (Topical)
  • 23 Jul 2026 Recce Pharmaceuticals received HREC approval to phase III trial for Diabetic foot ulcer in Australia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top